Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase‑9 (MMP‑9) and their complex MMP‑9/NGAL in sera and urine of patients with kidney tumors

Di Carlo,Angelina

doi:10.3892/ol.2013.1252

Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase‑9 (MMP‑9) and their complex MMP‑9/NGAL in sera and urine of patients with kidney tumors

Authors:
- Angelina Di Carlo
View Affiliations

Affiliations: Department of Medico-Surgical Sciences and Biotechnologies, ‘Sapienza’ University of Rome, I-Rome 00161, Italy
Published online on: March 13, 2013 https://doi.org/10.3892/ol.2013.1252
Pages: 1677-1681

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent evidence suggests that neutrophil gelatinase-associated lipocalin (NGAL) is required for the development and/or progression of benign and malignant disease, and is overexpressed in several types of tumor. Matrix metalloproteinase-9 (MMP-9), by degrading components of the extracellular matrix and thus promoting the release of growth factors, is important in tumor growth and tumorigenicity. NGAL protects MMP-9 from proteolytic degradation and enhances its enzymatic activities by binding and forming the MMP-9/NGAL complex. Therefore, NGAL, MMP-9 and their complex MMP-9/NGAL have been proposed as soluble biomarkers for numerous malignancies. In the present study, we measured the concentration of these molecules in sera and urine of patients with kidney disease using ELISA. Of these patients, 16 had clear cell renal cell carcinoma (ccRCC) and 4 had oncocytoma. Sera and urine samples of 53 healthy patients were used as controls. In sera, MMP-9 was enhanced in ccRCC patients compared with oncocytoma patients. In urine, the most abundant molecule was NGAL and its mean value was higher in cancer patients. However, there was a broad overlap of the data and we did not identify any correlation with disease type, stage or grade. Therefore, these molecules may not be useful as biomarkers for predicting kidney carcinoma.

View Figures

View References

1	Flower DR: The lipocalin protein family: structure and function. Biochem J. 318:1–14. 1996.
2	Di Carlo A: The enigmatic role of lipocalin 2 in human cancer. The multifunctional protein neutrophil gelatinase-associated lipocalin (NGAL) and its ambiguous role in human neoplasias. Prevent Res. 2: View Article : Google Scholar
3	Triebel S, Bläser J, Reinke H and Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 314:386–388. 1992. View Article : Google Scholar : PubMed/NCBI
4	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
5	Björklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
6	Yan L, Borregaard N, Kjeldsen L and Moses MA; The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP and neutrophil gelatinase-associated lipocalin (NGAL): Modulation of MMP-9 activity by NGAL. J Biol Chem. 276:37258–37265. 2001. View Article : Google Scholar : PubMed/NCBI
7	Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Bertger T, Mak TW, Knebelmann B, Friedlander G, Barasch J and Terzi F: Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest. 120:4065–4076. 2010. View Article : Google Scholar : PubMed/NCBI
8	Chakraborty S, Kaur S, Guha S and Batra SK: The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta. 1826:129–169. 2012.PubMed/NCBI
9	Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A and Buemi M: Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 52:595–605. 2008. View Article : Google Scholar : PubMed/NCBI
10	Cho H and Kim JH: Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem. 57:513–521. 2009. View Article : Google Scholar : PubMed/NCBI
11	Wang HJ, He XJ, Ma YY, Jiang XT, Xia YJ, Ye ZY, Zhao ZS and Tao HQ: Expression of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and ancillary diagnostic test. Anat Rec (Hoboken). 293:1855–1863. 2010. View Article : Google Scholar : PubMed/NCBI
12	Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, Nonni A, Papassotiriou I and Zografos G: Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer. 9:3902009. View Article : Google Scholar
13	Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, Lele SM, Ouellette M, Pour PM, Sasson AR, Brand RE, Hollingsworth MA, Jain M and Batra SK: Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 98:1540–1547. 2008. View Article : Google Scholar
14	Sobin LH and Wittekind CH; International Union Against Cancer (UICC): TNM Classification Of Malignant Tumors. 6th edition. New York, NY: Wiley-Liss; pp. 193–195. 2002
15	Kashyap MK, Kumar A, Emelianenko N, Kashyap A, Kaushik R, Huang R, Khullar M, Sharma SK, Singh SK, Bhargave AK and Upadhyaya SK: Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers. 10:258–294. 2005. View Article : Google Scholar : PubMed/NCBI
16	Di Carlo A: Matrix metalloproteinase-2 and -9 in the sera and in the urine of human oncocytoma and renal cell carcinoma. Oncol Rep. 28:1051–1056. 2012.PubMed/NCBI
17	Barresi V, Ieni A, Bolignano D, Magno C, Buemi M and Barresi G: Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: Correlation with histotype and histological grade. Oncol Rep. 24:305–310. 2010. View Article : Google Scholar : PubMed/NCBI
18	Perrin C, Patard JJ, Jouan F, Collet N, Théoleyre S, Edeline J, Zerrouki S, Laguerre B, Bellaud-Roturaud MA, Rioux-Leclercq N and Vigneau C: The neutrophil gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness in clear cell renal carcinoma. Prog Urol. 21:851–858. 2011.In French.
19	Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I and Canipari C: Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 77:809–815. 2010. View Article : Google Scholar
20	Morrissey JJ, London AN, Lambert MC and Kharasch ED: Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma. Am J Nephrol. 34:391–398. 2011. View Article : Google Scholar : PubMed/NCBI
21	Fernández CA, Yan L, Louis G, Yang J, Kutok JL and Moses MA: The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 11:5390–5395. 2005.
22	Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D and Moses MA: Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 14:6610–6617. 2008. View Article : Google Scholar
23	Smith ER, Zurakowski D, Saad A, Scott RM and Moses MA: Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 14:2378–2386. 2008. View Article : Google Scholar : PubMed/NCBI